Tuesday, September 4, 2018

Earth Science Tech, Inc. (ETST) Expanding Reach and Products Globally


  • Strategically positioned to be a global leader in the CBD space
  • Expands CBD chocolate product line and provides accessibility to consumers in convenience stores across the U.S.
  • Joint ventures globally in nutraceuticals, pharmaceuticals and medical device products
Earth Science Tech, Inc. (OTC: ETST) is a Florida-based biotechnology company focused on cannabis (industrial hemp) and cannabinoid research and development, nutraceuticals, pharmaceuticals and medical devices. The company operates through three wholly owned subsidiaries – Earth Science Pharmaceutical Inc., Cannabis Therapeutics Inc. and KannaBidioiD, Inc. – each of which are equally invested in developing the company’s role as a global leader in the CBD space. Last year, the company acquired Canna Inno Laboratories, Inc. as part of its strategic plan to expand into Canada and gain access to government grants.

By making its products more available to consumers through its association with AATAC, an advisory board that focuses on convenience stores, ETST is setting itself apart as a major provider of premium CBD products. Through a joint venture with Karmavore Superfoods, the company is expanding its unique full spectrum cannabinoid CBD raw dark chocolate line from two to five products. With the anticipated launch of three new CBD-based patent formulas – chocolate-covered mangoes, chocolate coconut peppermint cups and chocolate caramelized quinoa crunch – ETST and AATAC anticipate a high volume of preorders from approximately 90,000 retail outlets throughout the United States. These chocolates are scheduled to hit the market in the coming weeks. The move to provide this product in convenience stores provides ETST with the means to increase its consumer base across every sector of the population. In a news release  (http://ibn.fm/3NhlP), Jill Buzan, chief sales officer of ETST, stated, “This could lead to huge exponential growth for ETST’s sales in the next few months.”

The expanded reach throughout the United States is not the company’s only focus. Its goal is to become a global leader in the CBD space, and ETST is taking promising steps in that direction.

In March, ETST announced that it had received a grant from the Government of Quebec to pursue the development of three CBD-based nutraceutical provisional patent products. These products include a neuron protector, a breast protector and a product designed to improve antioxidant ingestion.

Through a joint venture with Bionatus Laboratrio Botnico of Brazil and its Canadian division, Bionatus Botanical Laboratories, Inc., ETST has three products in various stages. Propovit’s purpose is to alleviate throat irritation, colds and bad breath, and it is enriched with ETST hemp oil. Bionatus is being reformulated with the addition of CBD to potentially enhance its anti-inflammatory and bronchial-dilation properties. A third product is in the planning stages, and details will be shared soon.

A pre-launch clinical study of ‘Hygee’ with Clinique Santé Amitié in Quebec, Canada, is currently being conducted. ‘Hygee’ is the name of ETST’s MSN-2 home testing medical kit designed for the detection of sexually transmitted infections (STI), such as chlamydia. This kit will be marketed worldwide, and the company anticipates approval of the trademark within the next nine to 10 months.

For more information, visit the company’s website at www.EarthScienceTech.com

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html